ATM and pancreatic ductal adenocarcinoma: Another study by Hannan et al. showed that the ATM mutation may be prognostic for improved outcomes in patients with pancreatic ductal adenocarcinoma, with overall survival of 40.2 months as compared to 15.5 months in patients without a pathogenic variant of ATM (HR 0.14, 95% CI: 0.04–0.47) [57].